Roles of microRNAs in Ovarian Cancer Tumorigenesis: Two Decades Later, What Have We Learned?

被引:62
|
作者
Alshamrani, Ali A. [1 ]
机构
[1] King Saud Univ, Dept Pharmacol & Toxicol, Coll Pharm, Riyadh, Saudi Arabia
来源
FRONTIERS IN ONCOLOGY | 2020年 / 10卷
关键词
microRNA; ovarian cancer; proliferation; biomarkers; chemoresistance; diagnosis; prognosis; target genes; GLUTATHIONE-S-TRANSFERASE; SUPPRESSES TUMOR-GROWTH; PROMOTES CELL-GROWTH; CISPLATIN RESISTANCE; DOWN-REGULATION; MIR-200; FAMILY; UP-REGULATION; ENHANCES CHEMOSENSITIVITY; MULTIDRUG-RESISTANCE; INHIBITS METASTASIS;
D O I
10.3389/fonc.2020.01084
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ovarian cancer is one of the top gynecological malignancies that cause deaths among females in the United States. At the molecular level, significant progress has been made in our understanding of ovarian cancer development and progression. MicroRNAs (miRNAs) are short, single-stranded, highly conserved non-coding RNA molecules (19-25 nucleotides) that negatively regulate target genes post-transcriptionally. Over the last two decades, mounting evidence has demonstrated the aberrant expression of miRNAs in different human malignancies, including ovarian carcinomas. Deregulated miRNAs can have profound impacts on various cancer hallmarks by repressing tumor suppressor genes. This review will discuss up-to-date knowledge of how the aberrant expression of miRNAs and their targeted genes drives ovarian cancer initiation, proliferation, survival, and resistance to chemotherapies. Understanding the mechanisms by which these miRNAs affect these hallmarks should allow the development of novel therapeutic strategies to treat these lethal malignancies.
引用
收藏
页数:19
相关论文
共 50 条
  • [1] Two Decades of IDPs; What have we Learned?
    Kriwacki, Richard
    Mitrea, Diana M.
    Follis, Ariele
    Iconaru, Luigi
    Cika, Jaclyn
    Ban, David
    Philllips, Aaron
    BIOPHYSICAL JOURNAL, 2017, 112 (03) : 12A - 13A
  • [2] Two Decades of Nursing Home Compare: What Have We Learned?
    Tamara Konetzka, R.
    Yan, Kevin
    Werner, Rachel M.
    MEDICAL CARE RESEARCH AND REVIEW, 2021, 78 (04) : 295 - 310
  • [3] Hereditary ovarian and breast cancer: what have we learned?
    Lynch, H. T.
    Snyder, C.
    Casey, M. J.
    ANNALS OF ONCOLOGY, 2013, 24 : 83 - 95
  • [4] Nitric oxide signaling in the retina: What have we learned in two decades?
    Vielma, Alex H.
    Retamal, Mauricio A.
    Schmachtenberg, Oliver
    BRAIN RESEARCH, 2012, 1430 : 112 - 125
  • [5] Preterm labor and birth: What have we learned in the past two decades?
    Moore, ML
    JOGNN-JOURNAL OF OBSTETRIC GYNECOLOGIC AND NEONATAL NURSING, 2003, 32 (05): : 638 - 649
  • [6] Management of cystic echinococcosis in the last two decades: what have we learned?
    Velasco-Tirado, Virginia
    Romero-Alegria, Angela
    Pardo-Lledia, Javier
    Alonso-Sardon, Montserrat
    Lopez-Bernus, Amparo
    Quinones Sampedro, Jose
    Munoz Bellvis, Luis
    Iglesias Gomez, Alicia
    Muro, Antonio
    Munoz Bellido, Juan Luis
    Iglesias-Iglesias, Manuel
    Jimenez Lopez, Marcelo Fernando
    Belhassen-Garcia, Moncef
    TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2018, 112 (05) : 207 - 215
  • [7] Two Decades of Behavioral Research on Analytical Procedures: What Have We Learned?
    Messier, William F., Jr.
    Simon, Chad A.
    Smith, Jason L.
    AUDITING-A JOURNAL OF PRACTICE & THEORY, 2013, 32 (01): : 139 - 181
  • [8] Randomized experiments in criminology: What have we learned in the last two decades?
    Farrington D.P.
    Welsh B.C.
    Journal of Experimental Criminology, 2005, 1 (1) : 9 - 38
  • [9] Two decades of organizational change in health care: What have we learned?
    Bazzoli, GJ
    Dynan, L
    Burns, LR
    Yap, C
    MEDICAL CARE RESEARCH AND REVIEW, 2004, 61 (03) : 247 - 331
  • [10] Seroma Formation after Breast Cancer Surgery: What We Have Learned in the Last Two Decades
    Srivastava, Vivek
    Basu, Somprakas
    Shukla, Vijay Kumar
    JOURNAL OF BREAST CANCER, 2012, 15 (04) : 373 - 380